ArticleEuropean radiology2026
Deep learning model for noninvasive prediction of Ki-67 expression and prognostic stratification in breast cancer: a multicenter retrospective study.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveKi-67 correlates with prognosis for patients with breast cancer. However, the evaluation of Ki-67expression relies on pathological analysis and invasive biopsy, which hinders its wide adoption. This work sought to develop a noninvasive Ki-67 prediction model for breast cancer patients through ultrasound and clinical information and evaluate model performance in risk stratification of lymph metastasis and prognosis. MATERIALS AND
methodsClinical, ultrasound, pathological, and prognostic information were collected from four centers to develop a deep learning (DL) model. Ultrasound features were extracted by ResNet-50 and integrated with clinical information through logistic regression. Class activation mapping and nomograms were used to visualize the prediction process. Area under curve (AUC), confusion matrices, calibration curves, and decision curve analysis were used to evaluate model performance on Ki-67. Prognostic relevance was evaluated with lymph node metastasis and recurrence-free survival (RFS).
resultsFrom January 2021 to December 2024, 456 patients from three centers were collected as training (n = 264), validation (n = 96), and internal test (n = 96) sets, 204 patients from an independent center were collected as an external test set. In the external set, the combined model achieved satisfactory performance on Ki-67 (AUC = 0.828, 95% CI: 0.761-0.890). High Ki-67 group showed higher lymph metastasis rates (67.7% vs 16.2%, p < 0.001) and worse RFS (p = 0.041) than the low Ki-67 group. The combined model achieved the best predictive ability on recurrence in the first 6 months after operation (AUC = 0.820).
conclusionThis noninvasive model could predict Ki-67 status, classify the risk of lymph metastasis, and provide prognostic insights. Its wide application would contribute to the formulation of individualized treatment plans and follow-up strategies. KEY POINTS: Question Ki-67 is an important pathological information in breast cancer and is meaningful for lymph metastasis and prognosis. However, it can currently only be evaluated through invasive testing. Findings We developed a non-invasive model based on ultrasound and clinical information, which can predict Ki-67 status (accuracy = 0.828), classify lymph metastasis (accuracy = 0.765), and provide prognostic insights (p = 0.041). Clinical relevance This model enabled preoperative prediction of Ki-67 status and lymph metastasis for patients with breast cancer, thereby informing surgical planning. Furthermore, it demonstrated prognostic utility, facilitating the development of personalized patient follow-up strategies.
Indexed as
Identifiers
42095876What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.